|
Pronunciation |
|
(ay
za SYE ti
deen) |
|
|
U.S. Brand
Names |
|
Mylosar® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
AZA-CR; 5-Azacytidine; 5-AZC; Ladakamycin; NSC-102816 |
|
|
Pharmacological Index |
|
Antineoplastic Agent, Miscellaneous |
|
|
Use |
|
Refractory acute lymphocytic and myelogenous leukemia |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Liver disease |
|
|
Adverse
Reactions |
|
>10%:
Central nervous system: Coma (at doses of 300-750 mg/m2)
Gastrointestinal: Nausea, vomiting, diarrhea, mucositis
Hematologic: Leukopenia, thrombocytopenia,
1% to 10%:
Cardiovascular: Hypotension,
Central nervous system: Coma
Dermatologic: Rash
Hepatic: Hepatic abnormalities (increased enzyme levels up to coma)
Renal: Renal toxicity (azotemia, hypophosphatemia, tubular acidosis)
|
|
|
Stability |
|
Refrigerate |
|
|
Usual Dosage |
|
Children and Adults: I.V., S.C.: 50-200 mg/m2/day for 5-10 days,
repeated at 2- to 3-week intervals or 75 mg/m2/day for 7 days
every 4 weeks |
|
|
Administration |
|
Administer I.V. via bolus or continuous infusion |
|
|
Mental Health: Effects
on Mental Status |
|
High doses may produce coma |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Leukopenia is common; use caution with clozapine and
carbamazepine |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Nausea and vomiting may occur. Adhere to recommended antiemetic regimen.
Subcutaneous injection may cause redness, swelling, or mild
pain. |
|
|
Nursing
Implications |
|
Administer by slow infusion over <3 hours; may be administered
S.C. |
|
|
Dosage Forms |
|
Injection: 100 mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|